Skip to main content
SpringerLink
Log in

Thyroid Cancer: Impact of Therapeutic Modalities on Prognosis

  • Chapter
Thyroid Cancer

Part of the book series: Endocrine Updates ((ENDO,volume 2))

Abstract

The prognosis of thyroid carcinoma is determined by an interaction of three variables: tumor stage, the patient=s age at the time of diagnosis, and the efficacy of therapy. Tumor stage is largely due to the inherent biologic potential of a neoplasm to invade tissues and metastasize to distant sites, and to a lesser extent to the timeliness of diagnosis. Treatment is the only prognostic variable that currently can be modified.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97:418–428.

    PubMed  CAS  Google Scholar 

  2. Parker SL, Johnston Davis K, Wingo PA, Ries LAG, Heath CW, Jr. Cancer statistics, 998. CA 1998; 48:6–30.

    Google Scholar 

  3. Mazzaferri EL Thyroid carcinoma: Papillary and follicular. In: Mazzaferri EL, Samaan N, eds. Endocrine Tumors. Cambridge: Blackwell Scientific Publications Inc., 1993; 278–333.

    Google Scholar 

  4. Kosary CL, Ries LAG, Miller BA, Hankey BF, Harms A, Edwards BK. 1995 SEER Cancer Statistic Review, 1973–1992: Tables and Graphs. Bethesda, MD: National Cancer Institute. NIH Pub. No. 96–2789.

    Google Scholar 

  5. Crile GJ. Factors influencing the survival of patients with follicular carcinoma of the thyroid gland. Surg Gynecol Obstet 1985; 160:409–413.

    PubMed  Google Scholar 

  6. Simpson WJ, Panzarella T, Carruthers JS, Gospodarowicz MK, Sutcliffe SB. Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys 1988; 14:1063–1075.

    PubMed  CAS  Google Scholar 

  7. Carcangiu ML, Zampi G, Pupi A, Castagnoli A, Rosai J. Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer 1985; 55:805–828.

    PubMed  CAS  Google Scholar 

  8. Coburn M, Teates D, Wanebo HJ. Recurrent thyroid cancer: Role of surgery versus radioactive iodine (I131) Ann Surg 1994; 219:587–595.

    PubMed  CAS  Google Scholar 

  9. Byar DP, Green SB, Dor P, et al. A prognostic index for thyroid carcinoma. A study of the E.O.RT.C. Thyroid Cancer Cooperative Group. Eur J Cancer 1979; 15:1033–1041.

    PubMed  CAS  Google Scholar 

  10. Wanebo HJ, Andrews W, Kaiser DL. Thyroid Cancer: Some basic considerations. Am J Surg 1981; 142:474–479.

    PubMed  CAS  Google Scholar 

  11. Fourquet A, Asselain B, Joly J. Cancer de la thyroide: Analyse multidimensionnelle des facteurs pronostiques. Ann Endocrinol (Paris) 1983; 44:121–126.

    CAS  Google Scholar 

  12. Tubiana M, Schlumberger M, Rougier P, et al. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 1985; 55:794–804.

    PubMed  CAS  Google Scholar 

  13. Kerr DJ, Burt AD, Boyle P, MacFarlane GJ, Storer AM, Brewin TB. Prognostic factors in thyroid tumors. Br J Cancer 1986; 54:475–482.

    PubMed  CAS  Google Scholar 

  14. Joensuu H, Klemi PJ, Paul R, Tuominen J. Survival and prognostic factors in thyroid carcinoma. Acta Radiologica Oncol 1986; 25:243–248.

    CAS  Google Scholar 

  15. Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987; 102:1088–1095.

    PubMed  CAS  Google Scholar 

  16. Schelfhout LJ, Creutzberg CL, Hamming JF, Fleuren GJ, Smeenk D, Herman J. Multivariate analysis of survival in differentiated thyroid cancer: the prognostic significance of the age factor. Eur J Cancer 1988; 24:331–37.

    CAS  Google Scholar 

  17. Thoresen SO, Akslen LA, Glattre E, Haldorsen T, Lund EV, Schoultz M. Survival and prognostic factors in differentiated thyroid cancer--a multivariate analysis of 1,055 cases. Br J Cancer 1989; 59:231–235.

    PubMed  CAS  Google Scholar 

  18. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990; 71:414–424.

    PubMed  CAS  Google Scholar 

  19. Samaan NA, Schultz PN, Hickey RC, Haynie TP, Johnston DA, Ordonez NG. Well-differentiated thyroid carcinoma and the results of various modalities of treatment. A retrospective review of 1599 patients. J Clin Endocrinol Metab 1992; 75:714–720.

    PubMed  CAS  Google Scholar 

  20. Akslen LA, Haldorsen T, Thoresen SO, Glattre E. Survival and causes of death in thyroid cancer: a population-based study of 2479 cases from Norway. Cancer Res 1991; 51:1234–1241.

    PubMed  CAS  Google Scholar 

  21. Brennan MD, Bergstralh El, van Heerden JA, McConahey WM. Follicular thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 1991; 66:11–22.

    PubMed  CAS  Google Scholar 

  22. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma - A population-based study of 15,698 cases from the surveillance, epidemiology and end results (SEER) program 1973–1991. Cancer 1997; 79:564–573.

    PubMed  CAS  Google Scholar 

  23. Tsang RW, Brierley JD, Simpson WJ, Panzarella T, Gospodarowicz MK, Sutcliffe SB. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 1998; 82:375–388.

    PubMed  CAS  Google Scholar 

  24. McConahey WM, Hay ID, Woolner LB, van Heerden JA, Taylor WF. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: Initial manifestations, pathologic findings, therapy and outcome. Mayo Clin Proc 1986; 61:978–996.

    PubMed  CAS  Google Scholar 

  25. Viswanathan K, Gierlowski TC, Schneider AB. Childhood thyroid cancer: Characteristics and long-term outcome in children irradiated for benign conditions of the head and neck. Am J Dis Child 1994; 148:260–265.

    CAS  Google Scholar 

  26. Thoresen S, Akslen LA, Glattre E, Haldorsen T. Thyroid cancer in children in Norway 1953–1987. Eur J Cancer [A] 1993; 29A:365–366.

    CAS  Google Scholar 

  27. Frankenthaler RA, Sellin RV, Cangir A, Goepfert H. Lymph node metastasis from papillary-follicular thyroid carcinoma in young patients. Am J Surg 1990; 160:341–343.

    PubMed  CAS  Google Scholar 

  28. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988; 104:947–953.

    PubMed  CAS  Google Scholar 

  29. LiVolsi VA. Unusual variants of papillary thyroid carcinoma. In: Mazzaferri EL, Kreisberg RA, Bar RS, eds. Advances in Endocrinology and Metabolism. 6th ed. St. Louis: Mosby-Year Book, Inc., 1995; 39–54.

    Google Scholar 

  30. Johnson TL, Lloyd RV, Thompson NW, Beierwaltes WH, Sisson JC. Prognostic implications of the tall cell variant of papillary thyroid carcinoma. Am J Surg Pathol 1988; 12:22–27.

    PubMed  CAS  Google Scholar 

  31. Harach HR, Zusman SB. 1992 Cytopathology of the tall cell variant of thyroid papillary carcinoma. Acta Cytol (Baltimore) 1992; 36:895–899.

    CAS  Google Scholar 

  32. Leung C-S, Hartwick RWJ, Bédard YC. Correlation of cytologic and histologic features in variants of papillary carcinoma of the thyroid. Acta Cytol 1993; 37:645–650.

    PubMed  CAS  Google Scholar 

  33. Gimm O, Krause U, Wessel H, Finke R, Dralle H. Ectopic intrathyroidal thymus diagnosed as a solid thyroid lesion: Case report and review of the literature. J Pediatr Surg 1997; 32:1241–1243.

    PubMed  CAS  Google Scholar 

  34. Ritter A, Dreifes J, Jones M, Nishiyama R, Lennquist S. Overexpression of p53 in tall cell variants of papillary thyroid carcinoma. Surgery 1996; 120:1046–1050.

    Google Scholar 

  35. Ritter A, Nishiyama R, Lennquist S. Tall-cell variant of papillary thyroid cancer: Disregarded entity. World J Surg 1997; 21:15–21.

    Google Scholar 

  36. Sobrinho-Simoes. M.A., Nesland JM, Johannessen N. Columnar-cell carcinoma. Another variant of poorly differentiated carcinoma of the thyroid. Am J Clin Pathol 1988; 89:264–267.

    PubMed  CAS  Google Scholar 

  37. Fujimoto Y, Obara T, Ito Y, Kodama T, Aiba M, Yamaguchi K. Diffuse sclerosing variant of papillary carcinoma of the thyroid. Clinical importance, surgical treatment, and follow-up study. Cancer 1990; 66:2306–2312.

    PubMed  CAS  Google Scholar 

  38. Mizukami Y, Nonomura A, Michigishi T, et al. Diffuse sclerosing variant of papillary carcinoma of the thyroid. Report of three cases. Acta Pathol Jpn 1990; 40:676–682.

    PubMed  CAS  Google Scholar 

  39. Tielens ET, Sherman SI, Hruban RH, Ladenson PW. Follicular variant of papillary thyroid carcinoma: A clinicopathologic study. Cancer 1994; 73:424–431.

    PubMed  CAS  Google Scholar 

  40. Lang W, Choritz H, Hundeshagen H. Risk factors in follicular thyroid carcinomas:a retrospective follow-up study covering a 14-year period with emphasis on morphologic findings. Am J Surg Pathol 1986; 10:246–255.

    PubMed  CAS  Google Scholar 

  41. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med 1993; 328:553–559.

    PubMed  CAS  Google Scholar 

  42. van Heerden JA, Hay ID, Goellner JR, et al. Follicular thyroid carcinoma with capsular invasion alone: A nonthreatening malignancy. Surgery 1992; 112:1130–1138.

    PubMed  Google Scholar 

  43. Emerick GT, Duh Q-Y, Siperstein AE, Burrow GN, Clark OH. Diagnosis, treatment, and outcome of follicular thyroid carcinoma. Cancer 1993; 72:3287–3295.

    PubMed  CAS  Google Scholar 

  44. Donohue JH, Goldfien SD, Miller TR, Abele JS, Clark OH. Do the prognoses of papillary and follicular thyroid carcinomas differ? Am J Surg 1984; 148:168–173.

    PubMed  CAS  Google Scholar 

  45. Beierwaltes WH, Nishiyama RH, Thompson NW, Copp JE, Kubo A. Survival time and “cure” in papillary and follicular thyroid carcinoma with distant metastases: statistics following University of Michigan therapy. J Nucl Med 1982; 23:561–568.

    PubMed  CAS  Google Scholar 

  46. Balan KK, Raouf AH, Critchley M. Outcome of 249 patients attending a nuclear medicine department with well differentiated thyroid cancer; A 23 year review. Br J Radiol 1994; 67:283–291.

    PubMed  CAS  Google Scholar 

  47. Ruegemer JJ, Hay ID, Bergstralh EJ, Ryan JJ, Offord KP, Gorman CA. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab 1988; 67:501–58.

    PubMed  CAS  Google Scholar 

  48. Watson RG, Brennan MD, van Heerden JA, McConahey WM, Taylor WF. Invasive Hurthle cell carcinoma of the thyroid: Natural history and management. Mayo Clin Proc 1984; 59:851–855.

    PubMed  CAS  Google Scholar 

  49. Rosen IB, Luk S, Katz I. Hurthle cell tumor behavior: dilemma and resolution. Surgery 1985; 98:777–783.

    PubMed  CAS  Google Scholar 

  50. Thompson NW, Dunn EL, Batsakis JG, Nishiyama RH. Hurthle cell lesions of the thyroid gland. Surg Gynecol Obstet 1973; 139:555–560.

    Google Scholar 

  51. McDonald MP, Sanders LE, Silverman ML, Chan HS, Buyske J. Hurthle cell carcinoma of the thyroid gland: Prognostic factors and results of surgical treatment. Surgery 1996; 120:1000–1004.

    CAS  Google Scholar 

  52. Papotti M, Torchio B, Grassi L, Favero A, Bussolati G. Poorly differentiated oxyphilic (Hurthle cell) carcinomas of the thyroid. Am J Surg Pathol 1996; 20:686–694.

    PubMed  CAS  Google Scholar 

  53. Arganini M, Behar R, Wu TC, et al. Hurthle cell tumors: a twenty-five-year experience. Surgery 1986; 100:1108–1115.

    PubMed  CAS  Google Scholar 

  54. Samaan NA, Schultz PN, Haynie TP, Ordonez NG. Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients. J Clin Endocrinol Metab 1985; 60:376–380.

    PubMed  CAS  Google Scholar 

  55. Herrera MF, Hay ID, Wu PS, et al. Hurthle cell (oxyphyilic) papillary thyroid carcinoma: a variant with more aggressive biologic behavior. World J Surg 1994; 16:669–674.

    Google Scholar 

  56. Beckner ME, Heffess CS, Oertel JE. Oxyphilic papillary thyroid carcinomas. Am J Clin Pathol 1995; 103:280–287.

    PubMed  CAS  Google Scholar 

  57. Berho M, Suster S. The oncocytic variant of papillary carcinoma of the thyroid: A clinicopathologic study of 15 cases. Hum Pathol 1997; 28:47–53.

    PubMed  CAS  Google Scholar 

  58. Apel RL, Asa SL, LiVolsi VA. Papillary Hiirthle cell carcinoma with lymphocytic stroma: “Warthin-like tumor” of the thyroid. Am J Surg Pathol 1995; 19:810–814.

    PubMed  CAS  Google Scholar 

  59. Ezzat S, Sarti DA, Cain DR, Braunstein GD. Thyroid incidentalomas: Prevalence by palpation and ultrasonography. Arch Intern Med 1994; 154:1838–1840.

    PubMed  CAS  Google Scholar 

  60. Tan GH, Gharib H. Thyroid incidentalomas: Management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 1997; 126:226–231.

    PubMed  CAS  Google Scholar 

  61. Hay ID. Papillary thyroid carcinoma. Endocrinol Metabol Clin North Am 1990; 19:545–576.

    CAS  Google Scholar 

  62. Allo MD, Christianson W, Doivunen D. Not all “occult” papillary carcinomas are “minimal”. Surgery 1988; 104:971–976.

    PubMed  CAS  Google Scholar 

  63. LiVolsi VA. Papillary lesions of the thyroid. In: LiVolsi VA, ed. Surgical Pathology of the Thyroid. Philadelphia: W.B.Saunders Company, 1990; 136–172.

    Google Scholar 

  64. Mazzaferri EL. Papillary thyroid carcinoma: factors influencing prognosis and current therapy. Semin Oncol 1987; 14:315–332.

    PubMed  CAS  Google Scholar 

  65. DeGroot U, Kaplan EL. Second operations for “completion” of thyroidectomy in treatment of differentiated thyroid cancer. Surgery 1991; 110:936–940.

    PubMed  CAS  Google Scholar 

  66. Rao RS, Fakih AR, Mehta AR, Agarwal R, Raghavan A, Shrikhande SS. Completion thyroidectomy for thyroid carcinoma. Head Neck Surg 1987; 9:284–286.

    PubMed  CAS  Google Scholar 

  67. Auguste U, Attie JN. Completion thyroidectomy for initially misdiagnosed thyroid cancer. Otolaryngol Clin North Am 1990; 23:429–439.

    PubMed  CAS  Google Scholar 

  68. Crile GJ, Antunez AR, Esselstyn CBJ, Hawk WA, Skillem PG. The advantages of subtotal thyroidectomy and suppression of TSH in the primary treatment of papillary carcinoma of the thyroid. Cancer 1985; 55:2691–2697.

    PubMed  Google Scholar 

  69. Massin JP, Savoie JC, Gamier H, Guiraudon G, Leger FA, Bacourt F. Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment. Cancer 1984; 53:982–992.

    PubMed  CAS  Google Scholar 

  70. Cody HSI, Shah JP. Locally invasive, well-differentiated thyroid cancer. 22 years’ experience at Memorial Sloan-Kettering Cancer Center. Am J Surg 1981; 142:480–483.

    PubMed  Google Scholar 

  71. Salvesen H, Njolstad PR, Akslen LA, Albrektsen G, Soreide O, Varhaug JE. Papillary thyroid carcinoma: A multivariate analysis of prognostic factors including an evaluation of the p-TNM staging system. Eur J Surg 1992; 158:583–589.

    PubMed  CAS  Google Scholar 

  72. Hung W. Well-differentiated thyroid carcinomas in children and adolescents: a review. Endocrinologist 1994; 4:117–126.

    Google Scholar 

  73. De Keyser LFM, Van Herle M. Differentiated thyroid cancer in children. Head Neck Cancer 1985; 8:100–114.

    Google Scholar 

  74. Attie JN, Setzin M, Klein I. Thyroid carcinoma presenting as an enlarged cervical lymph node. Am J Surg 1993; 166:428–430.

    PubMed  CAS  Google Scholar 

  75. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993; 114:1050–1058.

    PubMed  CAS  Google Scholar 

  76. Cunningham MP, Duda RB, Recant W, Chmiel JS, Sylvester JA, Fremgen A. Survival discriminants for differentiated thyroid cancer. Am J Surg 1990; 160:344–347.

    PubMed  CAS  Google Scholar 

  77. Scheumann GFW, Gimm O, Wegener G, Hundeshagen H, Dralle H. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World I Surg 1994; 18:559–568.

    CAS  Google Scholar 

  78. Räsler H, Birrer A, Liischer D, Kinser J. Long-term course in differentiated thyroid carcinoma. Schweiz Med Wochenschr 1992; 122:1843–1857.

    Google Scholar 

  79. Sellers M, Beenken S, Blankenship A, et al. Prognostic significance of cervical lymph node metastases in differentiated thyroid cancer. Am J Surg 1992; 164:578–581.

    PubMed  CAS  Google Scholar 

  80. Coburn MC, Wanebo FU. Prognostic factors and management considerations in patients with cervical metastases of thyroid cancer. Am J Surg 1992; 164:671–676.

    PubMed  CAS  Google Scholar 

  81. McHenry CR, Rosen IB, Walfish PG. Prospective management of nodal metastases in differentiated thyroid cancer. Am J Surg 1991; 162:353–357.

    PubMed  CAS  Google Scholar 

  82. Hoie J, Stenwig AE, Kullmann G, Lindegaard M. Distant metastases in papillary thyroid cancer. A review of 91 patients. Cancer 1988; 61:1–6.

    PubMed  CAS  Google Scholar 

  83. Yamashita H, Noguchi S, Murakami N, Kawamoto H, Watanabe S. Extracapsular invasion of lymph node metastasis is an indicator of distant metastasis and poor prognosis in patients with thyroid papillary carcinoma. Cancer 1997; 80:2268–2272.

    PubMed  CAS  Google Scholar 

  84. Solan MJ. Multiple primary carcinomas as sequelae of treatment of pulmonary tuberculosis with repeated induced pneumothoraces. Case report and review of the literature. Am J Clin Oncol 1991; 14:49–51.

    PubMed  CAS  Google Scholar 

  85. Casara D, Rubello D, Saladini G, et al. Different features of pulmonary metastases in differentiated thyroid cancer: Natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 1993; 34:1626–1631.

    PubMed  CAS  Google Scholar 

  86. Schlumberger M, De Vathaire F, Travagli JP, et al. Differentiated thyroid carcinoma in childhood: long term follow-up of 72 patients. J Clin Endocrinol Metab 1987; 65:1088–1094.

    PubMed  CAS  Google Scholar 

  87. Brown AP, Greening WP, McCready VR, Shaw HJ, Harmer CL. Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experience. Br J Radiol 1984; 57:323–327.

    PubMed  CAS  Google Scholar 

  88. Schlumberger M, Tubiana M, De Vathaire F, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986; 63:960–967.

    PubMed  CAS  Google Scholar 

  89. Vassilopoulou-Sellin R, Klein MJ, Smith TH, et al. Pulmonary metastases in children and young adults with differentiated thyroid cancer. Cancer 1993; 71:1348–1352.

    PubMed  CAS  Google Scholar 

  90. Mazzaferri EL. Treating high thyroglobulins with radioiodine. A magic bullet or a shot in the dark?. J Clin Endocrinol Metab 1995; 80:1485–1487.

    PubMed  CAS  Google Scholar 

  91. Schlumberger M, Mancusi F, Baudin E, Pacini F. 131-I Therapy for elevated thyroglobulin levels. Thyroid 1997; 7:273–276.

    PubMed  CAS  Google Scholar 

  92. Hurley DL, Sizemore GW, McConahey WM. Prolonged remission of metastatic follicular thyroid carcinoma. Mayo Clin Proc 1993; 68:1205–1209.

    PubMed  CAS  Google Scholar 

  93. Maruyama M, Sugenoya A, Kobayashi S, Masuda H, Shimizu T, Iida F. A case of papillary carcinoma of the thyroid with more than 30 years long-term asymptomatic pulmonary metastases. Clin Endocrinol 1993; 38:331–336.

    CAS  Google Scholar 

  94. Brierley JD, Panzarella T, Tsang RW, Gospodarowicz MK, O’Sullivan B. A comparison of different staging systems predictability of patient outcome - Thyroid carcinoma as an example. Cancer 1997; 79:2414–2423.

    PubMed  CAS  Google Scholar 

  95. Loh KC, Greenspan FS, Gee L, Miller TR, Yeo PPB. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: A retrospective analysis of 700 patients. J Clin Endocrinol Metab 1997; 82:3553–3562.

    PubMed  CAS  Google Scholar 

  96. American Joint Committee on Cancer. Head and Neck Tumors. Thyroid Gland. In: Beahrs OH, Henson DE, Hutter RVP, Myers MH, eds. Manual for Staging of Cancer. 4th ed. Philadelphia: J.B.Lippincott, 1992; 53–54.

    Google Scholar 

  97. Shaha AR, Loree TR, Shah JP. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 1995; 118:1131–1138.

    PubMed  CAS  Google Scholar 

  98. Travagli JP, Schlumberger M, De Vathaire F, Francese C, Parmentier C. Differentiated thyroid carcinoma in childhood. J Endocrinol Invest 1995; 18:161–164.

    PubMed  CAS  Google Scholar 

  99. Zimmerman D, Hay I, Bergstralh E. 1992 Papillary thyroid carcinoma in children. In: Robbins J, ed. Treatment of thryoid cancer in childhood: Proceedings of a workshop held September 10–11, 1992, at the NIH in Bethesda MD. DOE/EH-0406, Springfield, VA: U.S. Dept of Commerce, 3–10.

    Google Scholar 

  100. Van De Velde CJH, Hamming JF, Goslings BM, et al. Report of the consensus development conference on the management of differentiated thyroid cancer in the Netherlands. Eur J Cancer Clin Oncol 1988; 24:287–292.

    Google Scholar 

  101. Ottino A, Pianzola HM, Castelletto RH. Occult papillary thyroid carcinoma at autopsy in La Plata, Argentina. Cancer 1989; 64:547–551.

    PubMed  CAS  Google Scholar 

  102. Solomon BL, Wartofsky L, Burman KD. Current trends in the management of well differentiated papillary thyroid carcinoma. J Clin Endocrinol Metab 1996; 81:333–339.

    PubMed  CAS  Google Scholar 

  103. Rosen IB, Bowden J, Luk SC, Simpson JA. Aggressive thyroid cancer in low-risk age population. Surgery 1987; 102:1075–1080.

    PubMed  CAS  Google Scholar 

  104. Jocham A, Joppich I, Hecker W, Knorr D, Schwarz HP. Thyroid carcinoma in childhood: Management and follow up of 11 cases. Eur J Pediatr 1994; 153:17–22.

    PubMed  CAS  Google Scholar 

  105. Utiger RD. Follow-up of patients with thyroid carcinoma. N Engl J Med 1997; 337:928–930.

    PubMed  CAS  Google Scholar 

  106. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338:297–306.

    PubMed  CAS  Google Scholar 

  107. Baldet L, Manderscheid JC, Glinoer D, Jaffiol C, Coste Seignovert B, Percheron C. The management of differentiated thyroid cancer in Europe in 1988 Results of an international survey. Acta Endocrinol (Copenh)1989; 120:547–558.

    Google Scholar 

  108. Filetti S, Belfiore A, Amir SM, et al. The role of thyroid-stimulating antibodies of Graves’ disease in differentiated thyroid cancer. N Engl J Med 1988; 318:753–79.

    PubMed  CAS  Google Scholar 

  109. Carayon P, Guibout M, Lissitzky S. Thyrotropin receptor-adenylate cyclase system in plasma membranes from normal and diseased human thyroid glands. J Endocrinol Invest 1978; 1:321–328.

    PubMed  CAS  Google Scholar 

  110. Dulgeroff AJ, Hershman JM. Medical therapy for differentiated thyroid carcinoma. Endocrinol Rev 1994; 15:500–515.

    CAS  Google Scholar 

  111. Dulgeroff AJ, Geffner ME, Koyal SN, Wong M, Hershman JM. Bmmocriptine and triac therapy for hyperthyroidism dur to pituitary resistance to thyroid hormone. J Clin Endocrinol Metab 1992; 75:1071–1075.

    PubMed  CAS  Google Scholar 

  112. Rossi RL, Cady B, Silverman ML, et al. Surgically incurable well-differentiated thyroid carcinoma. Prognostic factors and results of therapy. Arch Surg 1988; 123:569–574.

    PubMed  CAS  Google Scholar 

  113. Cady B, Cohn K, Rossi RL, et al. The effect of thyroid hormone administration upon survival in patients with differentiated thyroid carcinoma. Surgery 1983; 94:978–983.

    PubMed  CAS  Google Scholar 

  114. Mazzaferri EL. Thyroid cancer and Graves’ disease. J Clin Endocrinol Metab 1990; 70:826–829.

    PubMed  CAS  Google Scholar 

  115. Clark OH. TSH suppression in the management of thyroid nodules and thyroid cancer. World J Surg 1981; 5:39–47.

    PubMed  CAS  Google Scholar 

  116. Radetti G, Castellon C, Tató L, Platter K, Gentili L, Adami S. Bone mineral density in children and adolescent females treated with high doses of L-thyroxine. Horm Res 1993; 39:127–131.

    PubMed  CAS  Google Scholar 

  117. Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: A meta-analysis. Acta Endocrinol (Copenh) 1994; 130:350–356.

    CAS  Google Scholar 

  118. Panebianco P, Rosso D, Destro G, et al. Use of disphosphonates in the treatment of osteoporosis in thyroidectomized patients on levothyroxin replacement therapy. Arch Gerontol Geriatr 1997; 25:219–225.

    PubMed  CAS  Google Scholar 

  119. Biondi B, Fazio S, Carella C, et al. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1993; 77:334–338.

    PubMed  CAS  Google Scholar 

  120. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994; 331:1249–1252.

    PubMed  CAS  Google Scholar 

  121. Burmeister LA, Goumaz MO, Mariash CN, Oppenheimer JH. Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 1992; 75:344–350.

    PubMed  CAS  Google Scholar 

  122. Bartalena L, Martino E, Pacchiarotti A, et al. Factors affecting suppression of endogenous thyrotropin secretion by thyroxine treatment: retrospective analysis in athyreotic and goitrous patients. J Clin Endocrinol Metab 1987; 64:849–855.

    PubMed  CAS  Google Scholar 

  123. Wartofsky L. Use of sensitive TSH assay to determine optimal thyroid hormone therapy and avoid osteoporosis. Annu Rev Med 1991; 42:341–345.

    PubMed  CAS  Google Scholar 

  124. Wong JB, Kaplan MM, Meyer KB, Pauker SG. Ablative radioactive iodine therapy for apparently localized thyroid carcinoma. A decision analytic perspective. Endocrinol Metabol Clin North Am 1990; 19:741–760.

    CAS  Google Scholar 

  125. Beierwaltes WH, Rabbani R, Dmuchowski C, Lloyd RV, Eyre P, Mallette S. An analysis of “ablation of thyroid remnants” with I-131 in 511 patients from 1947–1984:Experience at University of Michigan. J Nucl Med 1984; 25:1287–1293.

    PubMed  CAS  Google Scholar 

  126. Goolden AWG. The indications for ablating normal thyroid tissue with 131-I in differentiated thyroid cancer. Clin Endocrinol 1985; 23:81–86.

    CAS  Google Scholar 

  127. Stael APM, Plukker JTM, Piers DA, Rouwé CW, Verney A. Total thyroidectomy in the treatment of thyroid carcinoma in childhood. Br J Surg 1995; 82:1083–1085.

    PubMed  CAS  Google Scholar 

  128. Mazzaferri EL. Thyroid remnant 131I ablation for papillary and follicular thyroid carcioma. Thyroid 1997; 7:265–271.

    PubMed  CAS  Google Scholar 

  129. DeGroot LJ, Reilly M. Comparison of 30- and 50-mCi doses of iodine-131 for thyroid ablation. Ann Intern Med 1982; 96:51–53.

    PubMed  CAS  Google Scholar 

  130. Maxon HR, Englaro EE, Thomas SR, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer -- a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 1992; 33:1132–1136.

    PubMed  Google Scholar 

  131. Maxon FIR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983; 309:937–941.

    PubMed  CAS  Google Scholar 

  132. Snyder J, Gorman C, Scanion P. Thyroid remnant ablation:Questionable pursuit of an ill-defined goal. J Nucl Med 1983; 24:659–665.

    PubMed  CAS  Google Scholar 

  133. Kuni CC, Klingensmith WC. Failure of low doses of 131-I to ablate residual thyroid tissue following surgery for thyroid cancer. Radiology 1980; 137:773–774.

    PubMed  CAS  Google Scholar 

  134. Siddiqui AR, Edmondson J, Wellman HN, et al. Feasibility of low doses of I-131 for thyroid ablation in postsurgical patients with thyroid carcinoma. Clin Nucl Med 1981; 6:158–161.

    PubMed  CAS  Google Scholar 

  135. Ramanna L, Waxman AD, Brachman MB, Tanasescu DE, Sensel N, Braunstein GD. Evaluation of low-dose radioiodine ablation therapy in postsurgical thyroid cancer patients. Clin Nucl Med 1985; 10:791–795.

    PubMed  CAS  Google Scholar 

  136. Johansen K, Woodhouse NJ, Odugbesan O. Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. J Nucl Med 1991; 32:252–254.

    PubMed  CAS  Google Scholar 

  137. Ozata M, Suzuki S, Miyamoto T, Liu RT, Fierro-Renoy F, DeGroot I.J. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 1994; 79:98–105.

    PubMed  CAS  Google Scholar 

  138. Nêmec J, Zamrazil V, Pohunková D, Röhling S. Radioiodide treatment of pulmonary metastases of differentiated thyroid cancer. Results and prognostic factors. Nuklearmedizin 1979; 18:86–90.

    PubMed  Google Scholar 

  139. McHenry C, Jarosz H, Davis M, Barbato AL, Lawrence AM, Paloyan E. Selective postoperative radioactive iodine treatment of thyroid carcinoma. Surgery 1989; 106:956–958.

    PubMed  CAS  Google Scholar 

  140. Mazzaferri EL. Carcinoma of follicular epithelium: radiodine and other treatment outcomes. In: Braverman LE, Utiger RD, eds. The Thyroid: A Fundamental and Clinical Text. 7th ed. Philadelphia: Lippencott-Raven Pub., 1996; 922–945.

    Google Scholar 

  141. Mazzaferri EL. Impact of initial tumor features and treatment selected on the long-term course of differentiated thyroid cancer. Thyroid Today 1995; 18:1–13.

    Google Scholar 

  142. National Cancer Institute. Cancer Statistics Review 1973–87. Bethesda, MD: U.S. Department of Health and Human Service, Public Health Service, National Institutes of Health, 1991; I.39-III.36.

    Google Scholar 

  143. Gorlin JB, Sallan SE. Thyroid cancer in childhood. Endocrinol Metabol Clin North Am 1990; 19:649–662.

    CAS  Google Scholar 

  144. Buckwalter JA, Gurll NJ, Thomas CGJ. Cancer of the thyroid in youth. World J Surg 1981; 5:15–25.

    PubMed  CAS  Google Scholar 

  145. La Quaglia MP, Corbally MT, Heller G, Exelby PR, Brennan MF. Recurrence and morbidity in differentiated thyroid carcinoma in children. Surgery 1988; 104:1149–1156.

    PubMed  Google Scholar 

  146. Goepfert H, Dichtel WJ, Samaan NA. Thryoid cancer in children and teenagers. Arch Otolaryngol 1984; 110:72–75.

    PubMed  CAS  Google Scholar 

  147. Harness JK, Thompson NW, McLeod MK, et al. Differentiated thyroid carcinoma in children and adolescents. World J Surg 1992; 16:547–554.

    PubMed  CAS  Google Scholar 

  148. Dottorini ME, Vignati A, Mazzucchelli L, Lomuscio G, Colombo L. Differentiated thyroid carcinoma in children and adolescents: A 37-year experience in 85 patients. J Nucl Med 1997; 38:669–675.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ohio State University, Columbus, OH, USA

    Ernest Mazzaferri M.D., M.A.C.P.

Authors
  1. Ernest Mazzaferri M.D., M.A.C.P.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Endocrinology & Metabolism Department of Medicine College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA

    James A. Fagin

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media New York

About this chapter

Cite this chapter

Mazzaferri, E. (1998). Thyroid Cancer: Impact of Therapeutic Modalities on Prognosis. In: Fagin, J.A. (eds) Thyroid Cancer. Endocrine Updates, vol 2. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4945-1_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-4945-1_11

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7244-8

  • Online ISBN: 978-1-4615-4945-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation